Seth A. Wander

5.3k total citations · 2 hit papers
108 papers, 2.9k citations indexed

About

Seth A. Wander is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Seth A. Wander has authored 108 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pulmonary and Respiratory Medicine, 62 papers in Oncology and 40 papers in Cancer Research. Recurrent topics in Seth A. Wander's work include Advanced Breast Cancer Therapies (74 papers), Cancer Treatment and Pharmacology (24 papers) and HER2/EGFR in Cancer Research (23 papers). Seth A. Wander is often cited by papers focused on Advanced Breast Cancer Therapies (74 papers), Cancer Treatment and Pharmacology (24 papers) and HER2/EGFR in Cancer Research (23 papers). Seth A. Wander collaborates with scholars based in United States, Italy and Israel. Seth A. Wander's co-authors include Joyce M. Slingerland, Aditya Bardia, Laura M. Spring, Bryan T. Hennessy, Dekuang Zhao, Beverly Moy, Amir Fathi, Nicholas C. Turner, Fabrice André and Jamie O. Brett and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Seth A. Wander

94 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

2020 312 citations Laura M. Spring, Seth A. Wander et al. profile →
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

2021 185 citations Laura M. Spring, Aditya Bardia et al. Breast Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Seth A. Wander United States	25	1.5k	1.3k	1.1k	791	389	108	2.9k
Judy Dering United States	23	2.2k 1.5×	1.5k 1.1×	1.3k 1.2×	902 1.1×	324 0.8×	41	3.6k
Violeta Sánchez United States	28	2.1k 1.4×	2.1k 1.6×	661 0.6×	840 1.1×	294 0.8×	59	3.8k
Shaozhen Xie United States	21	1.5k 1.0×	1.5k 1.1×	930 0.8×	392 0.5×	254 0.7×	30	3.0k
Andrew Krivoshik United States	19	876 0.6×	1.6k 1.2×	1.3k 1.1×	598 0.8×	481 1.2×	56	3.3k
Mónica V. Estrada United States	16	1.4k 0.9×	1.3k 1.0×	677 0.6×	925 1.2×	181 0.5×	25	2.5k
Diana Mandelker United States	23	867 0.6×	1.3k 1.0×	482 0.4×	718 0.9×	319 0.8×	94	2.5k
Marta Guzmán Spain	17	2.8k 1.9×	2.2k 1.7×	1.3k 1.1×	589 0.7×	551 1.4×	31	4.4k
Muralidhar Beeram United States	27	1.7k 1.2×	1.3k 1.0×	835 0.7×	380 0.5×	182 0.5×	89	3.0k
Christina R. Lee Canada	22	1.7k 1.1×	2.3k 1.7×	677 0.6×	1.6k 2.1×	310 0.8×	35	3.8k
Maurizio Voi United States	25	1.7k 1.1×	1.0k 0.8×	805 0.7×	525 0.7×	194 0.5×	68	3.1k

Countries citing papers authored by Seth A. Wander

Since Specialization

Citations

This map shows the geographic impact of Seth A. Wander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth A. Wander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth A. Wander more than expected).

Fields of papers citing papers by Seth A. Wander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seth A. Wander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth A. Wander. The network helps show where Seth A. Wander may publish in the future.

Co-authorship network of co-authors of Seth A. Wander

This figure shows the co-authorship network connecting the top 25 collaborators of Seth A. Wander. A scholar is included among the top collaborators of Seth A. Wander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seth A. Wander. Seth A. Wander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damodaran, Senthil, Massimo Cristofanilli, Matthew P. Goetz, et al.. (2024). Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study. Cancer Research. 84(9_Supplement). PO2–14. 1 indexed citations

Wang, Ming, et al.. (2024). Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). 1065–1065.

Lloyd, Maxwell R., Caroline Weipert, Jayati Saha, et al.. (2024). Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).. Journal of Clinical Oncology. 42(16_suppl). 1071–1071. 1 indexed citations

Wander, Seth A., Salomon M. Stemmer, Hope S. Rugo, et al.. (2024). Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC).. Journal of Clinical Oncology. 42(16_suppl). 1059–1059.

Wang, Ming, Laura Testa, Renata Colombo Bonadio, et al.. (2024). Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer. JCO Oncology Practice. 21(6). 832–842. 2 indexed citations

Bianchini, Giampaolo, M. Martín Jiménez, Stephanie L. Graff, et al.. (2024). 351P Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial. Annals of Oncology. 35. S362–S363.

Oliveira, Mafalda, Kyung Hae Jung, Sara A. Hurvitz, et al.. (2024). 365P Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC). Annals of Oncology. 35. S370–S371. 1 indexed citations

Gerratana, Lorenzo, Andrew A. Davis, Carolina Reduzzi, et al.. (2023). Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO Precision Oncology. 7(7). e2200531–e2200531. 7 indexed citations

Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations

10.

Wander, Seth A., et al.. (2023). Abstract P3-02-02: Real-World Time-to-Treatment Discontinuation in Hormone-Receptor-Positive Metastatic Breast Cancer Patients following CDK4/6 Inhibitor Treatment, Based on Observational Data Collected Through Patient-Partnered Research. Cancer Research. 83(5_Supplement). P3–2. 1 indexed citations

11.

Medford, Arielle J., Ignaty Leshchiner, Lesli A. Kiedrowski, et al.. (2023). ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1074–1074. 1 indexed citations

12.

Gerratana, Lorenzo, Andrew A. Davis, Katherine Clifton, et al.. (2023). Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. Breast Cancer Research. 25(1). 112–112. 7 indexed citations

13.

Stamou, Maria, Seth A. Wander, Jeffrey G. Supko, et al.. (2022). Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. JCO Precision Oncology. 6(6). e2100428–e2100428.

14.

Vidula, Neelima, Andrzej Niemierko, Jochen K. Lennerz, et al.. (2021). Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3404–3413. 12 indexed citations

15.

Juric, Dejan, Andrzej Niemierko, Laura M. Spring, et al.. (2020). Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology. 1246–1262. 15 indexed citations

16.

Mao, Pingping, Ofir Cohen, Kailey J. Kowalski, et al.. (2020). Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research. 26(22). 5974–5989. 90 indexed citations

17.

Drago, Joshua Z., Luigi Formisano, Dejan Juric, et al.. (2019). FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer. Clinical Cancer Research. 25(21). 6443–6451. 47 indexed citations

18.

Cornell, Liam, Seth A. Wander, Tanvi H. Visal, Nikhil Wagle, & Geoffrey I. Shapiro. (2019). MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Reports. 26(10). 2667–2680.e7. 108 indexed citations

19.

Picon‐Ruiz, Manuel, Katherine Drews‐Elger, Kibeom Jang, et al.. (2016). Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b–Mediated Malignant Progression. Cancer Research. 76(2). 491–504. 143 indexed citations

20.

Zhao, Dekuang, Seth A. Wander, Jia Sun, et al.. (2015). Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. 34(43). 5447–5459. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact